{
    "2020-08-25": [
        [
            {
                "time": "2023-10-01",
                "original_text": "Do AbbVie's (NYSE:ABBV) Earnings Warrant Your Attention?",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Earnings",
                        "Attention"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "AbbVie Submits Regulatory Application to FDA for RINVOQ™ (upadacitinib) for the Treatment of Adults with Active Ankylosing Spondylitis",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "FDA",
                        "RINVOQ",
                        "Ankylosing Spondylitis"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "The Daily Biotech Pulse: Altimmune Reports Positive Preclinical Data For Intranasal COVID-19 Vaccine, AbbVie Licenses Morphic's Drug, Viveve Clinical Readout",
                "features": {
                    "keywords": [
                        "Altimmune",
                        "Preclinical Data",
                        "Intranasal COVID-19 Vaccine",
                        "AbbVie",
                        "Morphic",
                        "Drug",
                        "Viveve",
                        "Clinical Readout"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "AbbVie, Harvard University Form Research Alliance to Address Emergent Viral Diseases",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Harvard University",
                        "Research Alliance",
                        "Emergent Viral Diseases"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "research"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Morphic Announces that AbbVie Exercises License Option to αvβ6 Integrin Inhibitor Program, Including MORF-720, for Fibrotic Diseases",
                "features": {
                    "keywords": [
                        "Morphic",
                        "AbbVie",
                        "License Option",
                        "αvβ6 Integrin Inhibitor",
                        "MORF-720",
                        "Fibrotic Diseases"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}